Depomed prevails in Gralise ANDA litigation with Actavis

20 August 2014

US drug maker Depomed (Nasdaq: DEPO) saw its shares climb more than 12% to $14.76 on Tuesday, on the news that the firm had received a positive court ruling relating to its Gralise (gabapentin).

Judge Joel Pisano of the US District Court for the District of New Jersey has ruled in favor of Depomed in the company's patent litigation law suit against generics major Actavis (NYSE: ACT), related to Actavis' Abbreviated New Drug Application for generic versions of Depomed's Gralisefor the management of post-herpetic neuralgia, the company announced.

Judge Pisano's ruling finds that Actavis infringes all seven Depomed patents asserted and upholds the validity of the patents. The latest expiration of the infringed patents is February 2024.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK